3 Swedish Stocks Estimated To Be Trading At Discounts Of Up To 40.9%
In This Article:
As global markets navigate shifting economic landscapes, the Swedish market has been influenced by recent monetary policy adjustments from the European Central Bank, which have sparked optimism for further easing. In this context of potential economic support, identifying undervalued stocks can be a strategic move for investors seeking opportunities in Sweden's evolving financial environment.
Top 10 Undervalued Stocks Based On Cash Flows In Sweden
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Sleep Cycle (OM:SLEEP) | SEK43.80 | SEK79.13 | 44.7% |
| Svedbergs Group (OM:SVED B) | SEK42.75 | SEK77.72 | 45% |
| Getinge (OM:GETI B) | SEK200.90 | SEK399.01 | 49.7% |
| Truecaller (OM:TRUE B) | SEK46.60 | SEK90.01 | 48.2% |
| Nolato (OM:NOLA B) | SEK52.45 | SEK103.31 | 49.2% |
| Wall to Wall Group (OM:WTW A) | SEK52.20 | SEK104.16 | 49.9% |
| TF Bank (OM:TFBANK) | SEK326.00 | SEK612.50 | 46.8% |
| Mentice (OM:MNTC) | SEK28.40 | SEK51.27 | 44.6% |
| Svedbergs Group (OM:SVED BTA B) | SEK36.30 | SEK65.51 | 44.6% |
| Bactiguard Holding (OM:BACTI B) | SEK45.00 | SEK85.45 | 47.3% |
Underneath we present a selection of stocks filtered out by our screen.
Betsson
Overview: Betsson AB (publ) operates and manages online gaming businesses across the Nordic countries, Latin America, Western Europe, Central and Eastern Europe, Central Asia, and internationally with a market cap of SEK38.45 billion.
Operations: The company's revenue segments include Casino at €605.50 million, Sportsbook at €402.30 million, and Other Products at €28.20 million.
Estimated Discount To Fair Value: 40.9%
Betsson AB is trading at SEK 138.94, significantly below its estimated fair value of SEK 235.23, indicating potential undervaluation based on cash flows. Despite a dividend yield of 5.31% not being well covered by free cash flows and recent shareholder dilution, the company shows promising growth prospects with earnings forecasted to grow faster than the Swedish market at 16.85% annually. Recent earnings reports show increased sales but slightly lower net income compared to last year.
-
The growth report we've compiled suggests that Betsson's future prospects could be on the up.
-
Click to explore a detailed breakdown of our findings in Betsson's balance sheet health report.
CellaVision
Overview: CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally, with a market cap of approximately SEK6.67 billion.
Operations: The company generates revenue of SEK726.40 million from its automated microscopy systems and reagents in the field of hematology.